^

Health

Enkad

, medical expert
Last reviewed: 23.04.2024
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Enkad helps eliminate the lack of nucleic acids that occurs in the body.

The drug contributes to the regulation of tissue metabolism of nucleotides, and at the same time demonstrates a pronounced immunomodulatory effect. It also helps to improve the activity of cell walls and muscle bio-energy. In addition, the drug weakens the myodystrophic processes occurring inside the body, and also helps to conduct impulses inside the motor neurons.

trusted-source[1], [2], [3]

Indications Enka

It is used in case of development of diseases affecting the eye retina (having a hereditary character). Among these, degeneration has a tapetretinal form (retinal abiotrophy - damage to the eye retina caused by a disorder of its nutritional processes).

Release form

The release of the drug substance is implemented as a lyophilisate; 3.5% injection fluid (pH values - in the range of 4.5-6.0) inside ampoules with a capacity of 2 or 3 ml. Inside the box are 10 such ampoules.

Dosing and administration

It is necessary to use the medication in the i / m way or subconjunctivally, and in addition through the phonophoresis procedure (therapeutic agents are introduced with the help of ultrasound through the complete mucous membranes) and with the help of local applications.

For daily intramuscular injections, an adult needs to use 175-210 mg per day (corresponding to 5-6 ml of 3.5% liquid). A child under the age of 7 years old is expected to take a daily dose of 10 mg / year; a child from 7 years old - 10.5 mg (corresponding to 3 ml of liquid) per day.

Daily dosage is used for 2 administrations with a 5-6 hour interval between them.

The therapeutic cycle should last 15 days. It is necessary to repeat the treatment with 6-8-10-month breaks, but at least 1-fold per year.

In addition to intramuscular injections, subconjunctival administration of the drug is also allowed - 0.3 ml of 3.5% liquid (corresponding to 10.5 mg), 1 time per day, in the period of 10-15 days.

During phonophoresis procedures, 0.5% encada fluid is used. It is necessary to prepare the medicinal solution immediately before the procedure. Treatment courses include 10–12 daily procedures; It is necessary to take such courses 2 times a year.

There is information regarding the use of the drug in the case of Sjogren's disease. It is believed that the positive therapeutic effect in this case is due to the immunomodulatory effect that medication provides.

In the case of the treatment of the above pathology, the drug is used in the form of applications to the region of the oral mucosa. For such procedures, apply a 1% solution (5 ml). The procedure lasts 20 minutes. Before use, the 3.5% liquid must be dissolved in isotonic NaCl (in a ratio of 1 to 3.5). It is necessary to perform applications 3 times a day (after eating a meal) in the period of 2 weeks. There are 3-4 such cycles per year.

trusted-source[6]

Use Enka during pregnancy

It is forbidden to use Enkad when breastfeeding or pregnancy.

Contraindications

Among the contraindications:

  • active infectious infections (including tuberculosis);
  • viral pathologies;
  • neoplasms;
  • diseases associated with the work of the cardiovascular system or the central nervous system (in severe);
  • renal / hepatic dysfunctions;
  • pathologies of allergic origin;
  • use in the elderly.

trusted-source[4], [5]

Side effects Enka

After the intramuscular injection of the drug, the temperature may increase, joint pain or chills may appear, as well as other allergy symptoms. In case of such violations, the medication is canceled, and the patient is undergoing desensitization treatment.

In order to prevent the emergence of strong side effects, before starting therapy, an intradermal test must be performed (sc with a method of injecting 0.1 ml of 3.5% drug liquid into the lower third zone of the forearm (from the inside of the hand)). If papules occur in this area that have a diameter of more than 1 cm, after a day has passed since the injection, it is considered that the sample gave a positive result - in this case the medicine cannot be used.

If the test gives a negative result, therapy can begin.

In the case of subconjunctival use, there may be hyperemia or edema in the conjunctival zone, which can be removed by instillation of the GCS substance. There may also be tenderness and an increase in the size of the lymph nodes in the cervical and parotid region.

Storage conditions

Enkad must be maintained at temperature values in the range of elevations + 4 / + 10 ° C.

trusted-source

Shelf life

Enkad can be used within a 2-year term from the date a pharmaceutical product is released.

trusted-source

Analogs

Analogues of the drug are drugs Peloidistilat and Actovegin, with placenta extract, and Thiogam with Aloe extract.

Reviews

Enkad generally receives good reviews from patients using it. But in some cases it is reported that it can lead to the appearance of negative symptoms.

Attention!

To simplify the perception of information, this instruction for use of the drug "Enkad" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.